{"id":48432,"date":"2022-09-15T15:01:50","date_gmt":"2022-09-15T13:01:50","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/zerigo-health-announces-release-of-eczema-solution\/"},"modified":"2022-09-15T15:01:50","modified_gmt":"2022-09-15T13:01:50","slug":"zerigo-health-announces-release-of-eczema-solution","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/zerigo-health-announces-release-of-eczema-solution\/","title":{"rendered":"Zerigo Health Announces Release of Eczema Solution"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nZerigo Health\u2019s latest software release includes integrated, guideline-recommended phototherapy dosing protocols for the treatment of atopic dermatitis (commonly referred to as eczema), in addition to its existing protocols for psoriasis\n<\/li>\n<li>\nEvernorth, Cigna\u2019s health services business, will offer Zerigo\u2019s solution as part of a pilot program through its Digital Health Formulary and is the first to launch this new platform for both psoriasis and eczema\n<\/li>\n<\/ul>\n<p>SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.zerigohealth.com%2Findex.html&amp;esheet=52895450&amp;newsitemid=20220915005063&amp;lan=en-US&amp;anchor=Zerigo+Health&amp;index=1&amp;md5=8a565587720e4c6008d749ad32fb507b\" rel=\"nofollow noopener\" shape=\"rect\">Zerigo Health<\/a>, which delivers the only connected light therapy solution for treating chronic skin conditions at home or on the go, today announced the launch of a new software release which includes integration of the American Academy of Dermatology Guideline protocols for the treatment of eczema with narrowband ultraviolet B (NB-UVB) phototherapy.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220915005063\/en\/1570974\/5\/CIG_EN_DHF_1x1_Pilot.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220915005063\/en\/1570974\/21\/CIG_EN_DHF_1x1_Pilot.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20220915005063\/en\/833918\/5\/LOGO_5.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220915005063\/en\/833918\/21\/LOGO_5.jpg\"><\/a><\/p>\n<p>\nEvernorth, Cigna Corporation\u2019s health services business, is the first to launch Zerigo\u2019s solution for both psoriasis and eczema, which will be offered as a pilot program through its Digital Health Formulary. The Evernorth Digital Health Formulary connects employers, insurers and patients with innovative, affordable, and evidence-based care that meets their broader health care needs. The pilot program will enable more people with chronic skin conditions to better manage their conditions.\n<\/p>\n<p>\n\u201cHealth plans and self-insured employers are already dealing with rapidly rising specialty drug costs for the treatment of psoriasis, which only affects 3.2% of the population but costs over $20 billion per year with a projected 20% annual growth rate, and now they are facing rising costs for the treatment of eczema,\u201d said John Schellhorn, Zerigo\u2019s President &amp; CEO. Schellhorn added, \u201cZerigo is uniquely positioned to help health plans and employers address these rising costs with guideline-recommended therapy and wraparound care support that generates positive health outcomes for members at a small fraction of the cost of these expensive drugs.\u201d\n<\/p>\n<p>\nWith the recent approval of five new specialty drugs indicated for the treatment of eczema and dozens more in development, analysts expect that specialty drug spend for eczema, which affects 7.3% of the U.S. population, will surpass that of psoriasis by the end of the decade.\n<\/p>\n<p>\nZerigo Health\u2019s FDA-cleared, natural light therapy solution safely and effectively shifts dermatological care from the clinic to the controlled convenience of home, keeping physicians and their patients with chronic skin conditions connected with personalized data and insights. Patients can easily self-administer clinically proven, American Academy of Dermatology guideline recommended NB-UVB phototherapy using a handheld device and smartphone app. Prescription dosing is controlled via secure cloud-based technology and personalized based on each patient\u2019s response to treatment, helping to ensure that patients treat safely in accordance with their physicians\u2019 prescriptions. Patients are also remotely monitored and provided personal coaching and support throughout their treatment journey.\n<\/p>\n<p>\n\u201cThe addition of eczema treatment protocols to our offering is one more significant step toward delivering our vision of empowering every person with a chronic skin condition to live confidently through personalized, connected, and cost-effective care,\u201d said Glen Tullman, Executive Chairman of Zerigo Health, CEO of Transcarent, and Managing Director of 7wireVentures. \u201cAt such an exciting time in the company\u2019s development, we are thrilled to collaborate with Evernorth to provide their members suffering from psoriasis and eczema access to the Zerigo Solution to drive better health outcomes at substantially lower costs than the existing alternatives.\u201d\n<\/p>\n<p>\n<b>About Zerigo Health<\/b>\n<\/p>\n<p>\nZerigo Health offers the only comprehensive home solution that seamlessly connects patients and providers to deliver optimal dermatological outcomes. Zerigo\u2019s precision solution remotely treats and monitors patients with chronic skin conditions using narrowband ultraviolet B (NB-UVB) phototherapy, a proven, standard-of-care treatment. Patients benefit from the unique combination of advanced technology with personal coaching and support throughout their treatment journey, which results in documented increases in treatment adherence and patient satisfaction. To learn more, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.zerigohealth.com&amp;esheet=52895450&amp;newsitemid=20220915005063&amp;lan=en-US&amp;anchor=www.zerigohealth.com&amp;index=2&amp;md5=db5f12c6c3417a9e76a9b5f4a555a6ad\" rel=\"nofollow noopener\" shape=\"rect\">www.zerigohealth.com<\/a> or on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fclarify-medical%2F&amp;esheet=52895450&amp;newsitemid=20220915005063&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=3&amp;md5=6a603cb95148837633447c23ddd1cc42\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a> or <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fzerigohealth&amp;esheet=52895450&amp;newsitemid=20220915005063&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=3ab33aa22d361a662c209e805918531c\" rel=\"nofollow noopener\" shape=\"rect\">Twitter<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nTeddy Fulham<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#97;&#x69;l&#116;&#x6f;&#x3a;t&#101;&#x64;&#x64;y&#46;&#x66;u&#108;&#x68;&#x61;m&#64;&#x7a;&#x65;r&#105;&#x67;o&#104;&#x65;&#x61;l&#116;&#x68;&#x2e;c&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#116;e&#x64;d&#x79;&#46;&#x66;&#117;&#x6c;&#104;&#x61;&#109;&#64;&#x7a;e&#x72;i&#x67;&#111;&#x68;&#101;&#x61;&#108;&#x74;&#104;&#46;&#x63;o&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Zerigo Health\u2019s latest software release includes integrated, guideline-recommended phototherapy dosing protocols for the treatment of atopic dermatitis (commonly referred to as eczema), in addition to its existing protocols for psoriasis Evernorth, Cigna\u2019s health services business, will offer Zerigo\u2019s solution as part of a pilot program through its Digital Health Formulary and is the first to &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/zerigo-health-announces-release-of-eczema-solution\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48432","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Zerigo Health Announces Release of Eczema Solution - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/zerigo-health-announces-release-of-eczema-solution\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zerigo Health Announces Release of Eczema Solution - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Zerigo Health\u2019s latest software release includes integrated, guideline-recommended phototherapy dosing protocols for the treatment of atopic dermatitis (commonly referred to as eczema), in addition to its existing protocols for psoriasis Evernorth, Cigna\u2019s health services business, will offer Zerigo\u2019s solution as part of a pilot program through its Digital Health Formulary and is the first to ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/zerigo-health-announces-release-of-eczema-solution\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-15T13:01:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220915005063\/en\/1570974\/21\/CIG_EN_DHF_1x1_Pilot.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zerigo-health-announces-release-of-eczema-solution\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zerigo-health-announces-release-of-eczema-solution\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Zerigo Health Announces Release of Eczema Solution\",\"datePublished\":\"2022-09-15T13:01:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zerigo-health-announces-release-of-eczema-solution\\\/\"},\"wordCount\":640,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zerigo-health-announces-release-of-eczema-solution\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220915005063\\\/en\\\/1570974\\\/21\\\/CIG_EN_DHF_1x1_Pilot.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zerigo-health-announces-release-of-eczema-solution\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zerigo-health-announces-release-of-eczema-solution\\\/\",\"name\":\"Zerigo Health Announces Release of Eczema Solution - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zerigo-health-announces-release-of-eczema-solution\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zerigo-health-announces-release-of-eczema-solution\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220915005063\\\/en\\\/1570974\\\/21\\\/CIG_EN_DHF_1x1_Pilot.jpg\",\"datePublished\":\"2022-09-15T13:01:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zerigo-health-announces-release-of-eczema-solution\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zerigo-health-announces-release-of-eczema-solution\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zerigo-health-announces-release-of-eczema-solution\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220915005063\\\/en\\\/1570974\\\/21\\\/CIG_EN_DHF_1x1_Pilot.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220915005063\\\/en\\\/1570974\\\/21\\\/CIG_EN_DHF_1x1_Pilot.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zerigo-health-announces-release-of-eczema-solution\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zerigo Health Announces Release of Eczema Solution\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zerigo Health Announces Release of Eczema Solution - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/zerigo-health-announces-release-of-eczema-solution\/","og_locale":"en_US","og_type":"article","og_title":"Zerigo Health Announces Release of Eczema Solution - Pharma Trend","og_description":"Zerigo Health\u2019s latest software release includes integrated, guideline-recommended phototherapy dosing protocols for the treatment of atopic dermatitis (commonly referred to as eczema), in addition to its existing protocols for psoriasis Evernorth, Cigna\u2019s health services business, will offer Zerigo\u2019s solution as part of a pilot program through its Digital Health Formulary and is the first to ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/zerigo-health-announces-release-of-eczema-solution\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-15T13:01:50+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220915005063\/en\/1570974\/21\/CIG_EN_DHF_1x1_Pilot.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/zerigo-health-announces-release-of-eczema-solution\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/zerigo-health-announces-release-of-eczema-solution\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Zerigo Health Announces Release of Eczema Solution","datePublished":"2022-09-15T13:01:50+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/zerigo-health-announces-release-of-eczema-solution\/"},"wordCount":640,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/zerigo-health-announces-release-of-eczema-solution\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220915005063\/en\/1570974\/21\/CIG_EN_DHF_1x1_Pilot.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/zerigo-health-announces-release-of-eczema-solution\/","url":"https:\/\/pharma-trend.com\/en\/zerigo-health-announces-release-of-eczema-solution\/","name":"Zerigo Health Announces Release of Eczema Solution - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/zerigo-health-announces-release-of-eczema-solution\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/zerigo-health-announces-release-of-eczema-solution\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220915005063\/en\/1570974\/21\/CIG_EN_DHF_1x1_Pilot.jpg","datePublished":"2022-09-15T13:01:50+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/zerigo-health-announces-release-of-eczema-solution\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/zerigo-health-announces-release-of-eczema-solution\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/zerigo-health-announces-release-of-eczema-solution\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220915005063\/en\/1570974\/21\/CIG_EN_DHF_1x1_Pilot.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220915005063\/en\/1570974\/21\/CIG_EN_DHF_1x1_Pilot.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/zerigo-health-announces-release-of-eczema-solution\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Zerigo Health Announces Release of Eczema Solution"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48432","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48432"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48432\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48432"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48432"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48432"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}